Phio Pharmaceuticals Corp.
PHIO
$1.98
-$0.16-7.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 52.95% | -- | |||
| Gross Profit | -52.95% | -- | |||
| SG&A Expenses | -27.17% | -9.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.28% | -16.93% | |||
| Operating Income | -5.28% | 16.93% | |||
| Income Before Tax | -6.69% | 17.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.69% | 17.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.69% | 17.44% | |||
| EBIT | -5.28% | 16.93% | |||
| EBITDA | -5.28% | 16.88% | |||
| EPS Basic | 7.11% | 57.46% | |||
| Normalized Basic EPS | 7.12% | 57.46% | |||
| EPS Diluted | 7.11% | 57.48% | |||
| Normalized Diluted EPS | 7.12% | 57.46% | |||
| Average Basic Shares Outstanding | 14.87% | 94.04% | |||
| Average Diluted Shares Outstanding | 14.87% | 94.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||